Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
|
|
- Dwight Cunningham
- 6 years ago
- Views:
Transcription
1
2 Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
3 Learning Objectives Upon completion of this presentation, learners should be better able to: Discuss some real-world HCV treatment issues related to choice of direct-acting antiviral (DAA) therapy in HIV-HCV coinfected patients Identify relevant drug interactions with DAAs and antiretroviral therapy Recognize the potential for adverse events in selected patients undergoing DAA therapy Highlight the importance of HCC surveillance even after HCV clearance in patients with cirrhosis
4 Milestones in HCV Treatment 100 HCV HIV/HCV Patients with SVR 12 (%) IFN/RBV PegIFN/RBV Telaprevir or Boceprevir + PR SMV or SOF + PR IFN-free DAAs
5 HIV-HCV Coinfected Responses to DAA Therapy Comparable to HCV Monoinfected Genotype 1 Regimen (12 weeks) HIV-HCV Coinfected HCV Monoinfected Study SVR Study SVR Daclatasvir + Sofosbuvir ALLY-2 97% AI % Ledipasvir-Sofosbuvir ION-4 96% ION-1 99% Paritaprevir-ritonavirombitasvir + Dasabuvir TURQUOISE-I 94% PEARL-III, IV 96% Elbasvir-Grazoprevir C-EDGE Coinf 95% C-EDGE TN 95%
6 HCV Targets for Direct-Acting Antivirals (DAAs) Receptor binding and endocytosis Transport and release Fusion and uncoating Virion assembly (+) RNA Translation NS3/4 and polyprotein protease processing inhibitors Membranous web NS5A inhibitors replication and assembly Adapted from Manns MP, et al. Nat Rev Drug Discov. 2007;6: NS5B polymerase RNA replication inhibitors Nucleos(t)ide Non-nucleoside
7 Currently Available DAAs Class Drug Dosing Activity FDA Approved NS5B inhibitor Sofosbuvir (Solvadi) QD Pangenotypic 2013 NS3A protease inhibitor (PI) NS5A-NS5B inhibitor combo NS5A, NS5B inhibitors with PI ( 3D ) NS5A inhibitor + PI NS5A inhibitor Simeprevir (Olysio) QD GT 1, 2, 4, 5, Ledipasvir-Sofosbuvir (Harvoni) Paritaprevir/ ritonavir/ombitasvir + dasabuvir (Viekira Pak) Ombitasvirparitaprevir/ritonavir (Technivie) Daclatasvir (Daclinza) NS5A inhibitor + PI Elbasvir-Grazoprevir (Zepatier) QD NS5A-NS5B inhibitor combo Sofosbuvir-Velpatasvir (Epclusa) QD GT BID GT QD GT QD Pangenotypic 2015 GT 1, 4 (pangenotypic) 2016 QD Pangenotypic 2016
8 Case 1 A 52 year-old HIV-infected man presents to your clinic for routine follow-up. On emtricitabine/tenofovir (FTC/TDF), ritonavir and atazanavir with a recent CD4 count 560 cells/mm 3 and HIV RNA <40 copies/ml. He has chronic hepatitis C, with HCV RNA level of 1.5 million IU/mL, genotype 1A, treatment naïve. His exam is notable for a firm liver edge and scattered spider angiomata. Labs show ALT 50, AST 60, platelets 110K; his CrCl is 75. His ultrasound demonstrates a nodular contoured liver and normal-sized spleen. He wants treatment for his hepatitis C infection.
9 Which of the following would you do next? A. Set him up for a liver biopsy for disease staging. B. Consider switching his antiretroviral regimen in anticipation of treatment with ledipasvir-sofosbuvir. C. Start elbasvir-grazoprevir once daily. D. Start ledipasvir-sofosbuvir plus ribavirin (weightbased dosing).
10 Factors to Consider in Choice of DAA Regimen Genotype (and subtype: 1A vs 1B) Cirrhosis? Decompensated or compensated? Treatment experience? Failure with peginterferon/ribavirin or prior DAAs? If HIV-coinfected: what is their antiretroviral therapy?
11 DAA Regimens: Genotype 1 GT 1A No cirrhosis GT 1A Cirrhosis, Naïve GT 1A Cirrhosis, PR Experienced GT 1B No cirrhosis GT 1B Cirrhosis, Naïve GT 1B Cirrhosis, PR Experienced EBR-GRZ LDV-SOF PrOD SOF-VEL SMV + SOF DCV + SOF 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks 12 weeks + RBV 12 weeks 12 weeks 12 weeks 12 weeks weeks weeks + RBV (or 24 weeks alone) (24 weeks + RBV) 12 weeks (24 weeks (+RBV if Q80K)) (24 weeks +/- RBV) 12 weeks 12 weeks 12 weeks 12 weeks weeks 12 weeks 12 weeks 12 weeks weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks + RBV (or 24 weeks alone) 12 weeks 12 weeks (24 weeks +/- RBV) (24 weeks +/- RBV)
12 Ledipasvir-Sofosbuvir (Harvoni) Indications and Usage - HCV genotypes 1, 4, 5, and 6 in adults - Patients co-infected with HIV and HCV Class & Mechanism - Ledipasvir: NS5A inhibitor - Sofosbuvir: Nucleotide analog NS5B polymerase inhibitor Dosing: Ledipasvir-Sofosbuvir (fixed dose 90 mg/400 mg): 1 tablet orally once daily with or without food Drug Interactions: Yes, but to a lesser extent than HCV protease inhibitors Adverse Effects (AE): Fatigue, headache Wholesale Cost: $94,500 for a 12-week course Source: Harvoni Prescribing Information. Gilead Sciences
13 Drug Interactions: ART and DAAs
14 Ledipasvir-Sofosbuvir & Tenofovir DF Ledipasvir increases tenofovir DF exposure by 30-60% when coadministered with boosted PI (which independently increases TDF levels). Avoid LDV and TDF if CrCl <60 Co-administered with r/pi Renal toxicity monitoring: Cr and UA at week 2, 4 and further as indicated Consider switch to TAF/FTC Source: Harvoni Prescribing Information. Gilead Sciences German P, CROI 2015, Abstract 82.
15 Case 2 A 60 year-old HIV-infected man presents to your clinic. On abacavir, dolutegravir and rilpivirine with a recent CD4 count 350 cells/mm 3 and HIV RNA <40 copies/ml. PMH: Burkitt s lymphoma in 2008 in remission. Hx TDF nephrotoxicity, hx M184V, and unable to tolerate PIs. He has chronic hepatitis C, with HCV RNA level of 800,000 IU/mL, genotype 1A, treatment naïve. FibroScan reveals F2 fibrosis. He has an isolated hep B core Ab and is immune to hepatitis A. You plan to prescribe ledipasvir-sofosbuvir (LDV/SOF). His insurance denies authorization of LDV-SOF but has elbasvirgrazoprevir (EBR-GRZ) on formulary.
16 Elbasvir-Grazoprevir (Zepatier) Indications and Usage - Chronic HCV genotypes 1 or 4 in adults - Patients with HIV-HCV coinfection Class & Mechanism - Elbasvir: HCV NS5A inhibitor - Grazoprevir: HCV NS3/4A protease inhibitor Dosing: Elbasvir-Grazoprevir (fixed dose 50 mg/100 mg) One tablet orally once daily, with or without food Drug Interactions: Yes substrate of CYP3A4 and PgP Adverse Effects (AE): - Fatigue, headache, nausea, rash (4%) - Increase in ALT > 5x normal in 1% of subjects Wholesale Cost: $54,600 for a 12-week course Source: Zepatier Prescribing Information. Merck & Co., Inc.
17 Drug Interactions: ART and DAAs
18 DAA Regimens: Genotype 1 GT 1A No cirrhosis GT 1A Cirrhosis, Naïve GT 1A Cirrhosis, PR Experienced GT 1B No cirrhosis GT 1B Cirrhosis, Naïve GT 1B Cirrhosis, PR Experienced EBR-GRZ LDV-SOF PrOD SOF-VEL SMV + SOF DCV + SOF 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks 12 weeks + RBV 12 weeks 12 weeks 12 weeks 12 weeks weeks weeks + RBV (or 24 weeks alone) (24 weeks + RBV) 12 weeks (24 weeks (+RBV if Q80K)) (24 weeks +/- RBV) 12 weeks 12 weeks 12 weeks 12 weeks weeks 12 weeks 12 weeks 12 weeks weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks + RBV (or 24 weeks alone) 12 weeks 12 weeks (24 weeks +/- RBV) (24 weeks +/- RBV)
19 Impact of Baseline NS5A RAVs in GT1a HCV treated with EBR-GRZ Patients without RAVs Patients with RAVs SVR12 (%) / / / / / / / / 150 EBR RAVs NS5A RAVs EBR RAVs NS5A RAVs Population Sequencing Next Generation Sequencing Jacobson I, et al. Gastroenterology. 2017, E-pub ahead of print.
20 Case 2 continued You send NS5A genotype 1 resistance testing. It returns showing Y93H mutation. You decide to start EBR-GRZ + ribavirin 600 mg BID for a planned duration of 16 weeks. Patient misses his week 2 CBC and returns 4 weeks into therapy with complaint of fatigue, irritability and malaise. Week 4 Labs: Hemoglobin 10 g/dl (from a baseline of 14). Total bilirubin is 3.2, ALT has risen to 365 (from 55) and AST 250 (from 40).
21 Which would you do next? A. Reduce the ribavirin from 1200 mg to 800 mg daily. B. Discontinue the ribavirin and continue elbasvirgrazoprevir. C. Send HBV DNA level. Consider stopping therapy pending these results. D. Wait for HCV RNA results to return before deciding what to do.
22 Factors to Consider in Choice of DAA Regimen Genotype (and subtype: 1A vs 1B) Cirrhosis? Decompensated or compensated? Treatment experience? Failure with peginterferon/ribavirin or prior DAAs? If HIV-coinfected: their antiretroviral therapy? Can they tolerate ribavirin? What is their insurance?
23 FDA Warning Oct 2016 HBV Reactivation on DAA Therapy Unexpected ALT and AST elevations 4-8 weeks (mean 53 days) from DAA initiation. Multiple kinds of DAA. Hospitalization in at least 6 patients. Severe clinical decompensation in 3 cases à 2 deaths and 1 liver transplantation. Among the 29 cases of HBV reactivation, 13 (45%) were chronic HBV carriers (+HBsAg). Some had absent HBsAg and anti-hbs, i.e. an isolated anti- HB core profile.
24 VA Cohort HBV Reactivation on DAA Therapy DAA treatment Hep B status HBV DNA tested on DAA HBV reactivation (>3 log 10 ) ALT peak not normal 62,920 HBsAg+ 377 (0.7%) Isolated core 7295* 84 (22%) 7 (8%) (2.4%) 1 (0.6%) 0 *18% of the 62% tested for core Ab (as well as sag/ab) Belperio, Hepatology E-published ahead of print.
25 Case 2 A 60 year-old HIV-infected man presents to your clinic. On abacavir, dolutegravir and rilpivirine with a recent CD4 count 350 cells/mm 3 and HIV RNA <40 copies/ml. PMH: Burkitt s lymphoma in 2008 in remission. Hx TDF nephrotoxicity and unable to tolerate PIs. He has chronic hepatitis C, with HCV RNA level of 800,000 IU/mL, genotype 1A, treatment naïve. FibroScan reveals F2 fibrosis. He has an isolated hep B core Ab and is immune to hepatitis A. You plan to prescribe ledipasvir-sofosbuvir (LDV/SOF). His insurance denies authorization of LDV-SOF but has elbasvirgrazoprevir (EBR-GRZ) on formulary.
26 Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir ( 3D, Viekira Pak) Indication: HCV Genotype 1 infection, including compensated cirrhosis Class & Mechanism - Ombitasvir: NS5A inhibitor - Paritaprevir: NS3/4A protease inhibitor - Ritonavir: HIV PI used as booster - Dasabuvir: NS5B inhibitor Dose: 2 tablets Ombitasvir-Paritaprevir-Ritonavir once daily with food plus Dasabuvir 1 tablet twice daily with food Adverse Effects (AE): Fatigue, pruritus, and insomnia Wholesale Cost: $83,319 for 12-week course Source: Viekira Pak Prescribing Information. Abbvie, Inc.
27
28 Coformulated DAAs for GT1 HCV Drug Pros Cons Ledipasvir-sofosbuvir (LDV-SOF) (Harvoni) Simplicity, even for cirrhotics Can use without RBV in most Few drug interactions Data in decompensated cirrhotics Cost Restrictive drug access program Approved only vs GT 1 Paritaprevir-ritonavirombitasvir + dasabuvir (PrOD) (Viekira Pak) Elbasvir-grazoprevir (EBR-GRZ) (Zepatier) Activity vs GT 4 (Technivie) Data in ESRD Simplicity in most patients Extensive data in ESRD Activity vs GT 4 Lower cost Works for PI-experienced pts Pill burden (esp + RBV) BID dosing w/ food Drug interactions Necessity of RBV with GT 1A Hepatoxicity (rare) avoid in decompensated pts Drug interactions NS5A resistance testing in GT 1A 16 week duration in some Hepatotoxicity (rare) avoid in decompensated pts RBV = ribavirin, IDUs = injection drug users, ESRD = end-stage renal disease
29 Case 3 A 45 year-old HIV-infected man presents to your clinic for routine follow-up. On FTC/TDF, ritonavir and darunavir with a recent CD4 count 560 cells/mm 3 and HIV RNA <40 copies/ml. Past Medical Hx: Diabetes mellitus, type 2 A1C 7% on metformin and GERD well controlled on omeprazole 20 mg BID Chronic hepatitis C, genotype 1A, stage 2 fibrosis on recent fibroscan. Has hx viral non-response to peginterferon + ribavirin in 2004.
30 DAA Regimens: Genotype 1 GT 1A No cirrhosis GT 1A Cirrhosis, Naïve GT 1A Cirrhosis, PR Experienced GT 1B No cirrhosis GT 1B Cirrhosis, Naïve GT 1B Cirrhosis, PR Experienced EBR-GRZ LDV-SOF PrOD SOF-VEL SMV + SOF DCV + SOF 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks 12 weeks + RBV 12 weeks 12 weeks 12 weeks 12 weeks weeks weeks + RBV (or 24 weeks alone) (24 weeks + RBV) 12 weeks (24 weeks (+RBV if Q80K)) (24 weeks +/- RBV) 12 weeks 12 weeks 12 weeks 12 weeks weeks 12 weeks 12 weeks 12 weeks weeks (*16 weeks + RBV if +NS5A RAV) 12 weeks + RBV (or 24 weeks alone) 12 weeks 12 weeks (24 weeks +/- RBV) (24 weeks +/- RBV)
31 Case 3 A 45 year-old HIV-infected man presents to your clinic for routine follow-up. On FTC/TDF, ritonavir and darunavir with a recent CD4 count 560 cells/mm 3 and HIV RNA <40 copies/ml. Past Medical Hx: Diabetes mellitus, type 2 A1C 7% on metformin and GERD well controlled on omeprazole 20 mg BID Chronic hepatitis C, genotype 1A, stage 2 fibrosis on recent fibroscan. Has viral non-response to peginterferon + ribavirin in You decide that ledipasvir-sofosbuvir is the simplest treatment option for patient at this time.
32 Question What medication changes would you want to make before starting ledipasvir-sofosbuvir in this patient? A. No changes current medications are fine. B. Discontinue metformin and switch to sulfonylurea. C. Reduce his omeprazole to 20 mg once daily or discontinue. D. Discontinue his ritonavir, darunavir and start dolutegravir. E. C and D.
33 Ledipasvir-Sofosbuvir & Proton Pump Inhibitors SVR12 (%) 90 No PPI PPI wks LDV-SOF 12 wks LDV-SOF Terrault, N et al. HCV-TARGET. Gastroenterol 2016;151:1131.
34 Tapper, N et al. TRIO Network. Hepatology 2016;64:1893.
35 Case 3 (continued) A 45 year-old HIV-infected man presents to your clinic for routine follow-up. On FTC/TDF, ritonavir and darunavir with a recent CD4 count 560 cells/mm 3 and HIV RNA <40 copies/ml. Past Medical Hx: Diabetes mellitus, type 2 A1C 7% on metformin and GERD well controlled on omeprazole 20 mg BID Chronic hepatitis C, genotype 1A, stage 2 fibrosis on recent fibroscan. Has viral non-response to peginterferon + ribavirin in Starts on dolutegravir (DTG), FTC/TDF. Omeprazole reduced to 20 mg once daily to be taken on empty stomach with LDV-SOF. Metformin was dose reduced for coadministration with DTG à A1C 10% on repeat testing.
36 Case 4 A 50 year-old HIV-infected man comes in for routine care after missing a few interval visits. He has been on FTC/TDF and dolutegravir, last CD4 count 630 cells/mm 3 and HIV undetectable in PMH: Obesity BMI 35 kg/m 2. Hx chronic hepatitis C genotype 3, stage 4 fibrosis who cleared with sofosbuvir + daclatasvir in At this visit, he is found to have ALT 200 and AST 350 (ALT and AST in 20s in Jan 2016). He notes some fatigue, anorexia and nausea. Denies any alcohol use, IVDU or sexual activity. His hepatitis A Ab (total) and Hep B surface Ab were both positive on entry into care.
37 For this patient, which of the following would you do next? A. Counsel patient that he should stop his ART given likely hepatotoxicity. B. Obtain ultrasound and serum alpha-fetoprotein. C. Arrange for CT or MRI liver protocol. D. Send hepatitis C antibody with reflexive RNA level. E. Send hepatitis A IgM antibody.
38 HCC in cirrhotic HCV patients Maintain surveillance after HCV clearance Risk of HCC in HCV cirrhotics à 1-3% per year. SVR associated with 76% reduction in HCC risk in long-term studies. But reduction in HCC risk is not immediate post-svr Possible risk in tumor recurrence or more diffuse/aggressive HCC post-daa suggested by a few recent European series. Morgan, Ann Intern Med. 2013;158: Reig, J Hepatol. 2016;65: Conti, J Hepatol. 2016;65:
39 Beste, Gastro. 2015;149:
40 HCC in cirrhotic HCV patients Risk Factors Age Severity of cirrhosis Diabetes, metabolic syndrome, obesity à NASH/NAFLD Male gender Alcohol Chronic hepatitis B coinfection HIV infection (low CD4) AASLD 2011 HCC Practice Guidelines. Akuta, Oncology. 2016;91: Gjaerde, Clin Infect Dis. 2016;63:821-9.
41
42 Nina Kim, MD MSc University of Washington Harborview Liver Clinic Questions?
43
Selecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationNext generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos
Next generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos Associate Professor of Gastroenterology, Academic Department of Gastroenterology, National and Kapodistrian University
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationDisclosures. Hepatitis C: the 2016 Perspective. The Take Home. Glossary 12/9/16
Disclosures Hepatitis C: the 2016 Perspective Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF I have received research grant support to UCSF related to HCV from the following:
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationHCV Case Studies (and Special Populations)
HCV Case Studies (and Special Populations) Case 1: Alfred 58 y/o man presents to clinic for primary care f/u. PMH: Hypertension, diabetes Medications: lisinopril, glipizide Allergies: NKDA Family History:
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationHepatitis C: a treatment revolution
Sunday, 10th July 2016 Michaelmas Cay 2 Room Concurrent 11 Health Innovation Hepatitis C: a treatment revolution Dr. Heather McNamee Hepatitis C a treatment revolution Dr Heather McNamee Medical Director
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationClinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Olysio) Reference Number: CP.CPA.289 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationHepatitis C: the 2015 Perspective for the Family Medicine Practitioner
Hepatitis C: the 2015 Perspective for the Family Medicine Practitioner Annie Luetkemeyer, MD Division of HIV,ID & Global Medicine San Francisco General Hospital Disclosures I have received research grant
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationNew York State HCV Provider Webinar Series. Treatment of HCV/HIV Co-Infection
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Objectives Review the epidemiology of HCV and HIV/HCV co-infection Discuss the burden of HIV/HCV co-infection Discuss the treatment
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: Last Review Date: 06.18
Clinical Policy: (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: 08.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Epclusa) Reference Number: CP.CPA.286 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationMy HCV patient is co-infected with HIV: how to manage?
EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg,
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Harvoni) Reference Number: CP.CPA.175 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationHepatitis C Virus Management
Hepatitis C Virus Management FORMATTED: 04/20/17 New York, New York: February 24, 2017 Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine University of California San Francisco San
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationBrief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)
Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationHepatitis C ew Medications, New Hope and New. V. Opportunities for Primary Care. Outline. HCV Disease Outcomes in the US 9/21/2016
Hepatitis C ew Medications, New Hope and New Opportunities for Primary Care Primary Care Principles and Practice October 14, 2016 Disclosures: Grant support Gilead Sciences, Inc Quality improvement Systematized
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationTreating Hepatitis C in Patients with Advanced Renal Disease
Treating Hepatitis C in Patients with Advanced Renal Disease Seyed Moayed Alavian M.D. Professor of Medicine, Hepatologist alavian@thc.ir Hemodialysis Patients hemodialysis Preventive Strategies Strict
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHepatitis C Virus Management
Hepatitis C Virus Management FDA-Approved Medications Hepatitis C is caused by a virus and results in liver inflammation, which can lead to advanced liver disease and/or liver cancer. An estimated 3 to
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationDisclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.
Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More information